Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.33, a 155.5% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15 price target.

https://theenterpriseleader.com/2019/11/24/seres-therapeutics-nasdaqmcrb-earns-buy-rating-from-hc-wainwright.html

..Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. The firm had revenue of $7.03 million during the quarter, compared to analyst estimates of $6.69 million. On average, sell-side analysts forecast that Seres Therapeutics will post -1.43 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nikko Asset Management Americas Inc. grew its position in Seres Therapeutics by 58.2% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 7,661,963 shares of the biotechnology company’s stock worth $30,724,000 after purchasing an additional 2,818,889 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in Seres Therapeutics by 58.2% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,661,963 shares of the biotechnology company’s stock worth $30,724,000 after purchasing an additional 2,818,889 shares during the last quarter. ARK Investment Management LLC grew its position in Seres Therapeutics by 33.1% in the 2nd quarter. ARK Investment Management LLC now owns 7,038,885 shares of the biotechnology company’s stock worth $22,665,000 after purchasing an additional 1,751,172 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in Seres Therapeutics in the 2nd quarter worth $8,050,000. Finally, BlackRock Inc. grew its position in Seres Therapeutics by 5.6% in the 2nd quarter. BlackRock Inc. now owns 2,323,332 shares of the biotechnology company’s stock worth $7,480,000 after purchasing an additional 122,803 shares during the last quarter. Institutional investors own 98.37% of the company’s stock.